An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK

Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction

(2012) Seul Gi Kang et al.   CARCINOGENESIS

The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis

(2011) Suzanne E. Mahady et al.   JOURNAL OF HEPATOLOGY

Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice

(2011) Michal Aharoni-Simon et al.   LABORATORY INVESTIGATION

Ajoene, A Stable Garlic By-Product, Inhibits High Fat Diet-Induced Hepatic Steatosis and Oxidative Injury Through LKB1-Dependent AMPK Activation

(2010) Chang Yeob Han et al.   ANTIOXIDANTS & REDOX SIGNALING

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetics of Oltipraz and Its Major Metabolite (RM) in Patients With Liver Fibrosis or Cirrhosis: Relationship With Suppression of Circulating TGF-β1

(2010) S G Kim et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation

(2010) Josep M. Orellana-Gavaldà et al.   HEPATOLOGY

Peroxisome Proliferator-activated Receptor γ Co-activator 1α (PGC-1α) and Sirtuin 1 (SIRT1) Reside in Mitochondria

(2010) Katia Aquilano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

(2010) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome

(2009) Bei B. Zhang et al.   Cell Metabolism

Oxidized Metabolites of Oltipraz Exert Cytoprotective Effects against Arachidonic Acid through AMP-Activated Protein Kinase-Dependent Cellular Antioxidant Effect and Mitochondrial Protection

(2009) Y. N. Kwon et al.   DRUG METABOLISM AND DISPOSITION

Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications

(2009) Elisa Fabbrini et al.   HEPATOLOGY

Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones

(2009) Seong Hwan Hwahng et al.   HEPATOLOGY

The role of PPARα in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARα actions

(2009) Michung Yoon   PHARMACOLOGICAL RESEARCH

Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome

(2008) Paul D. Berk   HEPATOLOGY

High-fat diets cause insulin resistance despite an increase in muscle mitochondria

(2008) C. R. Hancock et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AMPK: a metabolic gauge regulating whole-body energy homeostasis

(2008) Ricardo Lage et al.   TRENDS IN MOLECULAR MEDICINE